Publication & Citation Trends
Publications
0 total
FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: A phase 1B dose-expansion study.
Cited by 0
Semantic Scholar
KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC OA
Cited by 17
Semantic Scholar
A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
Cited by 0
Semantic Scholar
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas OA
Cited by 9
Semantic Scholar
A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.
Cited by 1
Semantic Scholar
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407 OA
Cited by 43
Semantic Scholar
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. OA
Cited by 39
Semantic Scholar
P35.04 The Prognostic Value of Metastasis to Different Organs in EGFR-Mutated Stage IV NSCLC Patients Treated with First-Line Icotinib OA
Cited by 0
Semantic Scholar
Research Topics
Acute Lymphoblastic Leukemia research
(27)
CAR-T cell therapy research
(19)
Acute Myeloid Leukemia Research
(11)
Cancer Genomics and Diagnostics
(11)
Biochemical and Molecular Research
(8)
Affiliations
Sun Yat-sen University
Shanghai Jiao Tong University
XinHua Hospital
Chinese National Human Genome Center
Shanghai Children's Medical Center